Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism?

Kidney International

Volumn 74, Issue 5, 2008, Pages 566-570

  Memon, Fahad ^a   El Abbadi, Mohga ^b   Nakatani, Teruyo ^a   Taguchi, Takashi ^c   Lanske, Beate ^a   Razzaque, M Shawkat ^a,c  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b University of Washington   (United States)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Calcification; Fgf23; Hyperphosphatemia; Klotho; NaPi2a

Indexed keywords

1,25 HYDROXYVITAMIN D; CALCIUM; FIBROBLAST GROWTH FACTOR 23; ION; KLOTHO PROTEIN; PHOSPHATE; UNCLASSIFIED DRUG; VITAMIN D;

BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; KIDNEY TUBULE ABSORPTION; MINERAL METABOLISM; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; SOFT TISSUE CALCIFICATION; VITAMIN BLOOD LEVEL;

ANIMALS; BLOOD VESSELS; CALCINOSIS; CONNECTIVE TISSUE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MICE; MICE, KNOCKOUT; MINERALS; MUTATION; PHOSPHATES; SIGNAL TRANSDUCTION; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIA;

EID: 49749093391     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.218     Document Type: Short Survey

References (48)

1. Sitara D, Razzaque MS, St-Arnaud R et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006; 169: 2161-2170.
2. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291: E38-E49.
3. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 2003; 285: E1-E9.
4. Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194: 1-10.
5. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 2000; 26: 345-348.
6. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505.
7. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 1656-1663.
8. Feng JQ, Ward LM, Liu S et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38: 1310-1315.
9. Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38: 1248-1250.
10. Goetz R, Beenken A, Ibrahimi OA et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007; 27: 3417-3428.
11. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281: 6120-6123.
12. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774.
13. Torres PU, Prie D, Molina-Bletry V et al. Klotho: an antiaging protein involved in mineral and vitamin D metabolism. Kidney Int 2007; 71: 730-737.
14. Nabeshima Y. Toward a better understanding of Klotho. Sci Aging Knowledge Environ 2006; 2006: pe11.
15. Razzaque MS, Sitara D, Taguchi T et al. Premature ageing-like phenotype in fibroblast growth factor 23 null mice is a vitamin-D mediated process. FASEB J 2006; 20: 720-722.
16. Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006; 12: 298-305.
17. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
18. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66.
19. Towler DA. Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol 2005; 25: 651-654.
20. El-Abbadi M, Giachelli CM. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench. Curr Opin Nephrol Hypertens 2005; 14: 519-524.
21. Raggi P, Ali O. Phosphorus restriction and control of coronary calcification as assessed by electron beam tomography. Curr Opin Nephrol Hypertens 2002; 11: 391-395.
22. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154.
23. Braun J, Asmus HG, Holzer H et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate - phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004; 62: 104-115.
24. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299.
25. Lomashvili KA, Khawandi W, O'Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2495-2500.
26. Hessle L, Johnson KA, Anderson HC et al. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 2002; 99: 9445-9449.
27. Poole KE, Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005; 5: 612-617.
28. Towler DA, Shao JS, Cheng SL et al. Osteogenic regulation of vascular calcification. Ann NY Acad Sci 2006; 1068: 327-333.
29. Hur DJ, Raymond GV, Kahler SG et al. A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A 2005; 135: 36-40.
30. Reddy J, Bilezikian JP, Smith SJ et al. Reduced bone mineral density is associated with breast arterial calcification. J Clin Endocrinol Metab 2008; 93: 208-211.
31. Marcovitz PA, Tran HH, Franklin BA et al. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 2005; 96: 1059-1063.
32. Lanske B, Razzaque MS. Premature aging in klotho mutant mice: cause or consequence? Ageing Res Rev 2007; 6: 73-79.
33. Razzaque MS, St-Arnaud R, Taguchi T et al. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant 2005; 20: 2032-2035.
34. Lanske B, Razzaque MS. Mineral metabolism and aging: the fibroblast growth factor 23 enigma. Curr Opin Nephrol Hypertens 2007; 16: 311-318.
35. Topaz O, Shurman DL, Bergman R et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36: 579-581.
36. Kato K, Jeanneau C, Tarp MA et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006; 281: 18370-18377.
37. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117: 2684-2691.
38. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435.
39. Inaba M, Okuno S, Imanishi Y et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17: 1506-1513.
40. Stompor T. An overview of the pathophysiology of vascular calcification in chronic kidney disease. Perit Dial Int 2007; 27(Suppl 2): S215-S222.
41. Cozzolino M, Mazzaferro S, Pugliese F et al. Vascular calcification and uremia: what do we know? Am J Nephrol 2007; 28: 339-346.
42. DeLoach SS, Berns JS. Arterial stiffness and vascular calcification in dialysis patients: new measures of cardiovascular risk. Semin Dial 2007; 20: 477-479.
43. Roos M, Lutz J, Salmhofer H et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf) 2008; 68: 660-665.
44. +-ATPase activity: solving the calcium metabolism dilemma? Nephrol Dial Transplant 2008; 23: 459-461.
45. Yoshida T, Fujimori T, Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 2002; 143: 683-689.
46. Miyamoto K, Ito M, Tatsumi S et al. New aspect of renal phosphate reabsorption: the type IIc sodium-dependent phosphate transporter. Am J Nephrol 2007; 27: 503-515.
47. Lanske B, Razzaque MS. Vitamin D and aging: old concepts and new insights. J Nutr Biochem 2007; 18: 771-777.
48. Razzaque MS. Can fibroblast growth factor 23 fine-tune therapies for diseases of abnormal mineral ion metabolism? Nat Clin Pract Endocrinol Metab 2007; 3: 788-789.